Corbus Pharmaceuticals to Present at the 14th Annual BIO

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

NORWOOD, MA--(Marketwired - Oct 13, 2015) -   Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the Company's Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at the 14 th Annual BIO Investor Forum on Wednesday, October 21, 2015 at 11:30 a.m. Pacific Time at the Parc 55 in San Francisco, California.

Dr. Cohen will provide an update on the Company's clinical development program for its investigational drug, Resunab™ , a novel synthetic oral drug with the potential to treat chronic inflammation and fibrosis in rare diseases. Resunab is currently being studied in three separate Phase 2 clinical trials for the treatment of cystic fibrosis , diffuse cutaneous systemic sclerosis and dermatomyositis .

A live audio webcast will be available by accessing the IR Calendar in the Investors section of the Corbus website ( www.CorbusPharma.com ). The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The 14 th Annual BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. BIO also produces the BIO International Convention , the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About Resunab ™ Resunab ™ is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab triggers the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab ™ , is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: Email Contact Media Contact David Schull or Marissa Goberdhan Russo Partners, LLC Phone: +1 (858) 717-2310 Email: Email Contact Email: Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 100

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

Kochav Defense Offers Class A Shares for Independent Trading

Updated Category News Views 100

Kochav Defense Initiates Separate Trading of Class A Shares Kochav Defense Acquisition Corp. (NASDAQ: KCHVU) has exciting news for its investors! Starting July 21, 2025, holders of the unit shares sold during its initial public offering will have the option to trade their Class A ordinary shares and rights separately. This development is expected to provide additional...

Continue Reading
CITGO Takes Active Steps in Community Safety Drills

Updated Category News Views 234

CITGO Lake Charles Refinery completed a significant emergency response drill back in 2024, engaging over 130 participants including local, state, and federal emergency responders. This Worst-Case scenario drill simulated operations on the waterway to bolster command capabilities during potential environmental incidents. Emergency Preparedness: The Core of CITGO's...

Continue Reading
Exploring Premium REITs for Reliable Cash Flow Generation

Updated Category News Views 196

Understanding High-Yield REIT Investments Investing in high-yield real estate investment trusts (REITs) is a popular strategy for those seeking attractive dividend income. REITs are uniquely designed to channel income back to their shareholders, making them an appealing choice for generating passive income streams. This article will explore several high-yield REITs that...

Continue Reading
Orchestra BioMed Strengthens Board with Industry Veteran

Updated Category News Views 180

Introduction of Christopher Cleary to the Orchestra BioMed Board Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is thrilled to announce a significant addition to its Board of Directors. Christopher Cleary, a monumental figure in the medical device industry, has joined the team as an independent member effective January 30, 2025. With over three decades of experience in...

Continue Reading
Microsoft's Latest Buyback Plan: What Investors Should Know

Updated Category News Views 202

Microsoft's Strategic Financial Moves Microsoft is making significant investments in its key areas while also ensuring it rewards its shareholders. As the tech giant ramps up its capital expenditures to improve cloud infrastructure—especially for artificial intelligence (AI)—it’s also keen on providing returns to its investors. Recently, the company announced a 10%...

Continue Reading